Receive report status and quick access to patient information /// EXPLORE NOW Tempus One: New AI Clinical Assistant Available for All Providers
Hero Background

LIFE SCIENCES

Discover, design, and deliver the right drug for the right patient

Tempus provides integrated solutions to help meet your needs from early discovery through commercialization.

We partner with scientists and researchers to accelerate the drug development process

  • 90%

    of the top 20 pharma oncology companies partner with Tempus

  • 200+

    biopharma partnerships

image description

Data Collaborations

  • 6M+

    de-identified research records to power scientific discovery to improve patient outcomes

  • 700K+

    records with matched clinical data linked with genomic information to understand driver mutations and outcomes associations

  • 150K+

    records with full transcriptomic data for interrogating tumor biology and mechanisms of action

image description

Sequencing

  • 6

    NGS tests to support clinical trial and research sequencing

  • 6K+

    oncologists rely on Tempus as their precision medicine partner

image description

Clinical Trial Solutions

  • 10

    days on average to activate a new site

  • 200+

    provider networks and research institutions in the TIME Trial® Program

  • 24K+

    patients have been identified for potential enrollment into clinical trials in our network

image description
Our Impact

Thanks to Tempus, we are able to identify patients that can be helped with our proprietary TMod™ platform. Without them, we wouldn’t be able to do this.

William Go, SVP, Head of Development at A2 Biotherapeutics (TMod™ is a trademark of A2 Biotherapeutics)

Our Impact

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Learn more about our partnership with Genmab
Our Impact

Bayer’s strong focus in precision medicine combined with Tempus’ unique testing offering has culminated in this collaboration to bring genomic testing to cancer patients.

Bhavesh Ashar, Senior Vice President, Head of U.S. Oncology at Bayer

Learn more about our partnership with Bayer
Our Impact

Our partnership with Tempus will enable us to collect important retrospective information about the patients enrolled in the dose escalation part of our clinical trial that we can potentially use to inform enrollment in the expansion stage of our study.

Jorge DiMartino, Chief Medical Officer and Executive Vice President, Clinical Development at Kronos Bio

Learn more about our partnership with Kronos

Featured Resources

View all RESOURCES
  • UPCOMING WEBINAR:

    The value of RNA sequencing in drug discovery

    Learn the value of RNA Sequencing in identifying genetic variants overexpressed in tumors that are measurable by RNA-Seq but not DNA-Seq.

    Read more
  • UPCOMING WEBINAR:

    Accelerating patient enrollment with just-in-time trials: TriHealth on the TIME program

    The traditional model of activating clinical trials is widely acknowledged as inefficient. The process of establishing a clinical site, negotiating partnerships between sites and sponsors, then attempting to recruit eligible patients in nearby areas can take many months, and it becomes a burden to trial site staff, sponsors, and patients.

    Read more
  • UPCOMING WEBINAR:

    Q&A: The evolution of RWE & HEOR—A conversation with two biopharmaceutical executives

    Dr. Gupta and Dr. Iyer discuss the evolution of RWD in HEOR with Dr. Sasser.

    Read more
  • UPCOMING WEBINAR:

    Q&A: Using liquid biopsies to build CDx in pancreatic cancer with Actuate Therapeutics

    Dr. Andrew Mazar of Actuate Therapeutics shares his perspective on liquid biopsy as a tool for CDx and drug development in pancreatic cancer.

    Read more
  • UPCOMING WEBINAR:

    AACR GSK Product Theater

    The Tempus Spotlight Theater this year was on “Delivering on the Promise of Precision Medicine: Leveraging Diagnostics and Data to Drive Next-Generation Drug Development” and was a fireside chat between Kate Sasser, Chief Scientific Officer at Tempus and Anne-Marie Martin, SVP Global Head in the Experimental Medicine Unit at GSK.

    View more
  • UPCOMING WEBINAR:

    The next evolution in drug development

    Hear from Janssen’s Dr. Najat Khan to find out how the company is applying advanced AI algorithms to RWD—with groundbreaking results.

    Read more
  • UPCOMING WEBINAR:

    New ways to optimize R&D partnerships

    Learn how Tempus and Kronos are partnering to leverage RWD’s potential to drive innovations in drug discovery and clinical development.

    Read more
  • UPCOMING WEBINAR:

    Enhanced biomarker discovery and design

    Combining sequencing, analytics, and data licensing with Tempus allows you to uncover new insights across R&D. Learn how one company made it happen.

    Read more
  • UPCOMING WEBINAR:

    Powering discovery: Tempus multimodal database

    Read about an example of how Tempus Multimodal Data enabled a pharmaceutical company to more quickly identify pancreatic cancer subtypes’ molecular signatures.

    Read more

Tempus empowers you to make smarter, faster, and more efficient decisions

Get customized solutions for your needs.